Mount Sinai Health System
Search
Profile image of Jamal Rahaman
Accepting New Patients
  • Treats Adults

Jamal Rahaman, MD

Obstetrics and Gynecology, Gynecologic Oncology

No Patient Experience Ratings
212-427-1415
View location details

Clinical Focus

Education

MD, University of the West Indies-Jamaica

Residency, Obstetrics & Gynecology

Mount Hope Maternity Hospital

Residency, Obstetrics & Gynecology

Lincoln Medical and Mental Health Center

Residency, Obstetrics & Gynecology

Mount Sinai Hospital

Fellowship, Thoracic Surgery (Cardiothoracic Vascular Surgery)

The Texas Heart Institute

Fellowship, Gynecologic Oncology

Mount Sinai Hospital

Certifications

American Board of Obstetrics and Gynecology

Awards

2010

Sydney Druce Award

Department of Obstetrics & Gynecology at Mount Sinai

2008

Best Doctors in New York

New York Magazine

2008

Marquis-Who's Who in America

2007

Biltmore Who's Who

2007

Top Doctor

US News & World Report

2007

Super Doctor

New York Times

2002

Top Doctors in New York Metro Area

Castle Conolly Medical

2002

1st Place

ACOG Annual Meeting Film Festival

2002

Top Minimal Invasive Surgeons

New York Magazine

2001

CREOG/ACOG National Faculty Teaching Award for Residency Education

1990

Resident of the Year Award

Lincoln Medical Center

1984

Class Prize in Internal Medicine

1984

Leonard de Cordova Medal in Physiology

1984

Noel Haye Prize in Anatomy

1979

University of the West Indies Open Scholarship

1979

Trinidad and Tobago National Scholarship

Research

Active Clinical Trials

GOG0218
A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women who are newly diagnosed, previously untreated, Stage III or IV, epithelial overian or primary peritoneal cancer NCI-supplied agent(s): Bevacizumab/Placebo (NSC #704865, IND #7921)

GOG0213 A Phase III randomized controlled clinical trial of Carboplatin and Paclitazel alone or in combination with Bevacizumab (NSC #704865, IND #7921) followed by Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritone primary and fallopian tube cancer.  NCI-supplied agents: Bevacizumab (NSC #704865, IND #7921)

GOG0212
A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or CT-2103 (IND #70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer achieve a complete clinical response to primary platinum/taxane chemotherapy

GOG0209
A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

GOG0210
A Molecular Staging Study of Endometrial Carcinoma

GOG0233 / ACRIN 6671
Utility of preoperative FDG-PET/CT and Ferumoxtran-10 MRI scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced (IB2, IIA ≥4 CM, IIB-IVA) carcinoma of the cervix

GOG0215
A Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries

GOG0136
Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer

GCO# 06-0832
Investigator Initiated Phase I/II trial of combination intra-peritoneal Docetaxel and intravenous pegylated liposomal doxorubicin in persistent epithelial ovarian, peritoneal and fallopian tube carcinoma.

GCO # 04-0754
A Phase lll, Double-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals ' HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age
Protocol 580299/008

GCO # 07-0267
A Phase lllb, Observer-Blind, Randomized, Multicenter Study With Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biological 's HPV-16/18 L 1/AS04 Vaccine Versus Merck 's Gardasil Vaccine When Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Protocol 108933 (HPV-010)

Translational Research

  • KLF6 is a novel regulator of VEGF in Ovarian cancer cell lines.
  • Utility of a novel microarray assessment of critical signaling pathways in ovarian cancer
  • MicroRNA signatures in Human Ovarian cancer and response to chemotherapy.
  • Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.
  • Combination anti-estrogen and proteosome inhibitor biologic therapy for uterine cancer.

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Industry Relationships